Table 2.

Summary of main findings

Analysis type	Subject	Identity	Working hypothesis	Experimental clues	References
Individual CK2 sites	Viral proteins	N	CK2 phosphosite inhibition/blockage by CIGB-300 impairs viral replication	Interaction, co-localization, N mRNA and protein expression inhibition by CIGB-300 in a subrogate model	Ramon et al. (2021)
Individual CK2 sites	Viral proteins	Orf6	CK2 phosphosite inhibition/blockage by CIGB-300 restores IFN signaling	Additive/Synergistic profile of CIGB-300 plus IFN alpha	Unpublished
Co-Expression and network propagation	Host and Viral Proteins	B23, Orf6, NUP98	CK2 phosphosite inhibition/blockage by CIGB-300 restores IFN signaling	Additive/Synergistic profile of CIGB-300 plus IFN alpha	Unpublished
Phosphoproteome overlap	Host Proteins	MATR3, SQSTM1, DIDO1	CIGB-300 Multitarget effect impairing viral transcription/splicing, inflammation, immunoresponse and apoptosis	Pulmonary lesions resolution in CT Phase I	Cruz et al. (2020)
Enrichment analysis at early viral infection and Kinase activity profiles	Host proteins	SRPK1 (SRSF1 and SRSF-2,6,10)	CIGB-300 impairs SRSF1 role in viral protein synthesis	None, to be evaluated in preclinical settings	NA
PPIs vs H125 Phosphoproteome	Host and Viral Proteins	Several proteins (see text and Fig. 7) [LARP1, LARP7, LARP4B]	CIGB-300 impairs Viral RNA processing and transcription	None, to be evaluated in preclinical settings	NA
SARS-CoV-2 vs H125 Phosphoproteome overlap, Network and Enrichment analysis	Host proteins	Several proteins (see text and Fig. 8) [HNRNPA1, HSPB1, SRRM2, SRRM1, B23]	CIGB-300 Multitarget effect impairing on mRNA metabolism, cell cycle and Autophagy pathways	Pulmonary lesions resolution in CT Phase I	Cruz et al. (2020)
Enrichment of Human Phenotypes	Host proteins	HNPRNPA1, MATR3, SQSTM1, B23, FIP1L1, NUMA1	CIGB-300 may relief Covid-19 clinical symptoms	To be evaluated in CT Phase II	NA